RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial

NCT06813820 | Recruiting DMC FDA Device

• 1 other identifier: CIP-0100
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 6

Brief Summary

A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary safety endpoint will be evaluated at 30 days. Primary efficacy endpoint will be at 1 year. Interim efficacy endpoints will be evaluated at 6 months.

Conditions

Left Ventricle Dilated; CHF; Left Ventricle Remodeling

Keywords

Left Ventricle Reverse remodeling

Outcome Measures

Primary Outcomes (3)

• Major Adverse Events Composite Performance Goal

  Composite of Major Adverse Events at 30 days comprised of Clinical Events Committee (CEC) Adjudication of Mortality, Myocardial Infarction (MI), Major Stroke, Prolonged Intubation \>48hrs, Need for Inotropic support \>24hrs, Mech circulatory support intra or post op, BARC 4 or 5 bleeding, reoperation, serious infection related to device or procedure, Cardiac tamponade, or Initiation of renal replacement therapy, with a Performance Goal (PG) of 70% (upper bound of the 97.5% one sided CI)

  30 days

• Composite Effectiveness Endpoint

  Using Finkelstein Schoenfeld (FS) hierarchical approach. This approach compares each treatment subject versus each control subject in a hierarchal fashion beginning with Kansas City Cardiomyopathy Questionnaire (+10 point improvement with higher score being better), 6 Minute Walk Test (+25meter improvement with longer distance being better), change in New York Heart Association (NYHA) Class (+1 point improvement with scale being 1 to 4 with lower value being better). Begin comparing at highest hierarchal assessment. If one group is "better than" the other, count as "win". If treatment and control subject equal at that assessment, compare to next hierarchal measure, if equal again, go to next until you have a "win". Compare overall wins versus loses for an overall win ratio.

  6 Months

• Composite Effectiveness Endpoint

  Using Finkelstein Schoenfeld (FS) hierarchical approach - Cardiovascular Mortality, Heart Transplant, Left Ventricular Assist Device (LVAD) Implantation, Hospital Readmission, Kansas City Cardiomyopathy Questionnaire (+10 point improvement with higher score being better), 6 Minute Walk Test (+25meter improvement with longer distance being better), change in New York Heart Association (NYHA) Class (+1 point improvement with scale being 1 to 4 with lower value being better). Begin comparing at highest hierarchal assessment. If one group is "better than" the other, count as "win". If treatment and control subject equal at that assessment, compare to next hierarchal measure, if equal again, go to next until you have a "win". Compare overall wins versus loses for an overall win ratio.

  12 Months

Study Arms (2)

Revivent System Therapy plus Guideline Directed Medical Therapy (GDMT)

EXPERIMENTAL

Medical Intervention through a mini thoracotomy, placement of anchors to plicate the scarred areas of the heart thereby reducing the left ventricle size and improving left ventricle mechanics. Subjects would continue on Guideline Directed Medical Therapy (GDMT)

Device: Revivent System

Guideline Directed Medical Therapy (GDMT) only

NO INTERVENTION

Subjects would remain on Guideline Directed Medical Therapy (GDMT) with no additional medical intervention.

Interventions

Revivent System DEVICE

BioVentrix has developed the Revivent System to mirror Surgical Ventricular Restoration (SVR). The Revivent System is used to place permanent cardiac implants to the epicardial surface for the purpose of reconfiguring abnormal cardiac geometry that is contributing to the dysfunction.

Revivent System Therapy plus Guideline Directed Medical Therapy (GDMT)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years old or older
• LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and/or dyskinetic) non-calcified scar
• Left Ventricular Ejection Fraction \< 40%
• Left ventricular end-systolic volume index ≥60 mL/m2
• Suffering from heart failure symptoms as defined by NYHA Classification \> 2 not responsive to medical therapy
• Patient completed 6 Minute Walk Test and KCCQ Quality of Life Questionnaire (can be performed at baseline visit)
• Patient is on adequate Guideline Directed Medical Therapy (GDMT)
• Subject or a legally authorized representative must provide written informed consent
• Agree to required follow-up visits
• Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure

You may not qualify if:

• Candidates will be excluded from the study if ANY of the following conditions is present:
• Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 90 days prior to enrollment
• Valvular heart disease, which in the opinion of the investigator, will require intervention (transcatheter or surgical)
• Mitral Regurgitation greater than moderate (\>2+)
• Need for coronary revascularization, in the opinion of the investigator
• Peak Systolic Pulmonary Arterial Pressure \> 70 mm Hg via echo or right heart catheterization
• Myocardial Infarction within 90 days prior to enrollment
• Within the last six months, a prior CVA or TIA, or intracranial hemorrhage
• Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission
• Severe pulmonary disease that would preclude general anesthesia
• Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac
• Chronic renal failure with a GFR\<30ml/min
• Subject is currently participating in another clinical trial that has not yet completed its primary endpoint

Sponsors & Collaborators

• BioVentrix: lead

Study Sites (6)

Banner University Medical Center

Phoenix, Arizona, 85012, United States

RECRUITING

Baptist Health South Florida

Miami, Florida, 33143, United States

RECRUITING

University of Chicago

Chicago, Illinois, 60637, United States

RECRUITING

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, 64131, United States

RECRUITING

Oklahoma Heart Hospital

Oklahoma City, Oklahoma, 73120, United States

RECRUITING

Penn State Health

Hershey, Pennsylvania, 717033, United States

RECRUITING

MeSH Terms

Conditions

Ventricular Remodeling

Condition Hierarchy (Ancestors)

Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Vinod THourani, MD

  Piedmont Healthcare

  PRINCIPAL INVESTIGATOR

• Marat Fudim, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Steve Chartier

CONTACT

(925) 830-1000; schartier@bioventrix.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 3, 2025
• First Posted: February 7, 2025
• Study Start: September 29, 2025
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2032
• Last Updated: February 20, 2026

Record last verified: 2026-02

Locations

US (6)